External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy. Issue 7 (23rd April 2015)

• Record Type: Journal Article
• Authors: Joliat, Gaëtan‐Romain; Petermann, David; Demartines, Nicolas; Schäfer, Markus
• Is Part Of: HPB. Volume 17:Issue 7(2015:Jul.)
• Page Start: 605
• Page End: 610
• Publication Date: 2015-04-23
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1111/hpb.12422
• Languages: English
• ISSNs: 1365-182X

Abstract

<abstract abstract-type="main" id="hpb12422-abs-0001"> <title>Abstract</title> <sec id="hpb12422-sec-0001" sec-type="section"> <title>Background</title> <p>Pancreaticoduodenectomies (PD) still have a substantial mortality rate. Recently, different scores have been published to predict the mortality risk pre‐operatively after PD. This retrospective study was designed to perform an external assessment of an Early Mortality Risk Score (EMRS).</p> </sec> <sec id="hpb12422-sec-0002" sec-type="section"> <title>Methods</title> <p>From 2000 to 2012, all PD cases performed at our institution were documented. Only patients treated for pancreatic head adenocarcinomas were included. Survival time and EMRS (based on age, tumour size, tumour differentiation and comorbidities) were calculated for every patient. Relative risks (RR) of early death 9 and 12 months after PD were then calculated.</p> </sec> <sec id="hpb12422-sec-0003" sec-type="section"> <title>Results</title> <p>Of 270 PD for various aetiologies, 120 PD for adenocarcinomas were included. The median follow‐up was 37 months, and the overall median survival was 19 months. EMRS of 4 showed a mortality RR of 5.1 at 9 months (<italic>P</italic> = 0.048) and of 4.5 at 12 months (<italic>P</italic> = 0.020).</p> </sec> <sec id="hpb12422-sec-0004" sec-type="section"> <title>Conclusions</title> <p>EMRS of 4 is a predictor of tumour‐related mortality at 9 and 12 months after PD for adenocarcinoma. The EMRS was externally assessed in our patient cohort and can be implemented in clinical practice. Clinical implications of this score still need to be studied.</p> </sec> </abstract>